After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback